EDSA Company Profile and Key Details

Edesa Biotech, Inc. (NASDAQ:EDSA) closed at $11.17 USD, gaining $3.91 (53.86%) from the previous close of $7.26. The stock is currently mid-range between its 52-week high and low $0.72 and $11.87. With a market capitalization of about $93.25 million, Edesa Biotech, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.68). Key stats such as the average daily volume over the past year has been around 4.57 million shares, trading with heavier-than-usual volume. Headquartered in Markham, ON, Edesa Biotech, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Pardeep Nijhawan, the company employs approximately 16 people and listed since June 21, 2010. Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs.

EDSA has shown mixed momentum, losing -1.35% over the past week and -38.07% over the past quarter, though year-to-date performance is up 2.82%. Short-term trend indicators are bullishly aligned (SMA20 38.43%, SMA50 17.22%, SMA200 -20.39%). The stock’s 14-day RSI is 62.64 (firm momentum), while the ATR of 0.21 points to moderate volatility. The stock remains hovering near 52-week lows, trading -47.49% below its high and over 115.28% above its low. Average 10-day trading volume of 2.01 million shares is below the 3-month average of 4.58 million, indicating normal recent market interest.

Edesa Biotech, Inc. generated EPS of -$1.15 over the past year. Five-year average earnings growth is -11.35%. Wall Street analysts project EPS growth of -1.04% annually over the next five years. The latest quarter delivered EPS of -$0.32. The next quarter is forecast at -$0.26. Next year's EPS is expected at $59.29. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers -55.24% upside. The low target suggests -55.24% downside. The mean target is $5.00. This offers -55.24% upside. Edesa Biotech, Inc. earnings surprise history is a mixed track record. The quarter that ended December 12, 2025, missed forecasts by 18.52%. The prior quarter beat by -3.85%. Over the last six quarters, Apple has recorded several small beats. These include -10.34% in August 09, 2024.